Laurs Labs has been added to the Dow Jones Best-In-Class (DJ BIC) World Index, recognizing their robust Environmental, Social, and Governance (ESG) performance. In 2026, they scored 81/100 on S&P Global's Corporate Sustainability Assessment.

The Nifty Pharma index has significantly outperformed the broader market, increasing by 11% over the past month while the Nifty 50 experienced a decline of 3.6%. Notable standouts in this sector include Gland Pharma with a impressive 27% gain, Laurus Labs at 23%, and Biocon showing a 21% rise.

Today on the National Stock Exchange (NSE), Lauras Labs experienced a significant block trade of approximately 137,809 shares valued at around INR 18.7 crore. This trade was conducted at a price of roughly INR 1,354.8 per share.

Pharmaceutical companies IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma, Wockhardt, Lupin, Divi's, Zydus, Torrent, JB Chem, Glenmark, and Ajanta have surged to their highest levels in the past year. Other notable gains were seen among stocks like these.

Experts suggest Bharti Airtel, VBL, and PB Fintech as potential stocks for immediate profits due to their bullish trends. Meanwhile, IPCA Labs and Laurus Labs display robust upward trends, making them attractive for short-term investments as well.

Pharmaceutical company Lauras Labs reaches a new record high of Rs 1,301.75 on May 14, 2026, indicating growing investor confidence in the pharma-biotech sector due to strong performance.

In a market experiencing weakness, Laurus Labs and Sai Life Sciences bucked the trend, increasing by 3%. These companies outperformed the Nifty 50's minor dip of 0.47%. Looking ahead, Laurus aims to achieve half of its revenue from Contract Development and Manufacturing Organizations (CDMO) by FY29, while Sai Life Sciences projects a compound annual growth rate (CAGR) of 25% for the period FY22-FY25, mainly due to increased exports to regulated markets.

On May 6, 2026, Laurus Labs reached an all-time high of Rs 1,186.80, surpassing its previous records. The company's shares have shown remarkable strength, outperforming both the broader market and its sector counterparts.

The pharmaceutical index Nifty Pharma reached a 52-week peak today at 24,033.45, registering a 2% increase. Notably, Wockhardt saw a 15% surge. Other companies like Lupin, Laurus, and Sun Pharma also hit new highs. Ajanta Pharma is experiencing strong growth in its branded business segment.

Laurus Labs shares rose by 6%, exhibiting a bullish flag pattern. The key supports are at ₹1,120 and ₹1,090, with the target price set at ₹1,300. This upward movement is attributed to its solid fundamentals, promising pipeline, and positive RSI/MACD indicators, suggesting potential growth. A break of ₹1,120 could initiate a correction in the stock's trajectory.

Today, Lauras Labs experienced a significant block trade on the National Stock Exchange (NSE), totaling approximately INR 118 crore for over a million shares. The transaction was finalized at INR 1,162.1 per share.

Kotak Equities maintains a 'Sell' rating on Laurus Labs due to a 8% Q4 EBITDA miss, attributed to weak Formulation Development and Manufacturing (FDF). Despite strong Contract Development and Manufacturing Organization (CDMO) growth and a long-term target being intact, high capital expenditure (around ₹30 billion) and expensive valuations (about 48 times FY28E P/E) constrain potential gains.

Goldman Sachs maintains a 'Sell' recommendation for Laurus Labs, predicting a target price of ₹1,000, despite Q4 sales growing by 5% and EBITDA increasing by 22%. However, the analysts express concern about weak topline guidance for FY27.

Lauras Labs (LAURUSLABS) will no longer offer its ₹1.20 dividend to shareholders purchasing after May 8, with the payment scheduled for May 30. Despite a modest payout ratio of 10%, the company's earnings per share have decreased by 3.2% annually over the past five years.

Lauras Labs and CDSL experienced lower-than-expected profits and revenues, with CDSL reporting a significant 13.7% drop in revenue and a 27.6% decline in EBITDA quarter over quarter. IndiaMART saw a steep 72% year-on-year profit decrease, while Sundram Fasteners reported a 14% decrease in EBITDA with steady margins at 15%.

Lauras Labs reported impressive Q4 FY26 results, achieving all-time highs in revenue and profitability, further enhancing its position as a mid-cap company. Although the stock experienced a minor daily price drop, investors continue to express optimism.

Laurs Labs is committing up to €9.8 million in joint venture KRKA Pharma Pvt Ltd for capital expenditure. Slovenia's KRKA d.d. matches this investment, maintaining a 51/49 ownership balance.

Laurus Labs has announced a dividend of ₹1.20 per share for the fiscal year 2026. The company's Annual General Meeting (AGM) will take place on July 2, 2026, with no modifications in the audit opinions regarding their financials.

Lauras Labs aims for a substantial revenue of INR 6,813 crore by FY26, marking a 23% growth, accompanied by an EBITDA margin of 26.8%. The company's strong financial position is evident as the reactor volume increases to 8,200 kL and net debt/EBITDA ratio remains at a manageable 1.0x.

Lauras Labs plans to increase its Contract Development and Manufacturing Organization (CDMO) revenue to half by 2030, investing approximately INR 3000 crores in capital expenditure.

Lauras Labs' share price dropped due to a missed Q4 revenue target, despite reporting an increase in profit margins.

Investors are urged to consider short-term investments in Jio Financial, Indian Bank, Laurus Labs, Bharat Dynamics, and Nalco, with predicted price increases for Jio Financial at Rs 258, Indian Bank at Rs 950, Laurus Labs at Rs 1,165, Bharat Dynamics at Rs 1,485, and Nalco at Rs 468.

Laurus Labs will host a Q4 and FY26 earnings conference call on April 30, 2026, at 5 PM IST, with an interactive Q&A session led by DAM Capital Advisors for discussion on their financial results.

Kush Bohra reveals his stock recommendations that include Tata Power, Laurus Labs, and Apollo Hospitals, offering buy/sell advice and target prices. He notes a positive outlook for Tata Steel and Jindal Steel but warns of sector rotation towards financials.

Investor Sagar Doshi suggests buying Laurus Labs, Data Patterns, and Syrma SGS, despite the market dip caused by escalating Middle East conflicts and increased tensions between US and Iran.

Midcap indices experienced a significant drop of 9-13%, with Bank Nifty falling 16%, due to escalating geopolitical tensions. However, the power and pharmaceutical sectors showed resilience, as stocks like Laurus and Premier Energies posted gains up to 21%.